PD-L1 imaging with [99mTc]NM-01 SPECT/CT predicts early metabolic response to pembrolizumab with or without chemotherapy in advanced non-small cell lung cancer (NSCLC): results from the PECan study.
Daniel Hughes, Gitasha Chand, Amelia E.B. Moore, Levente K. Meszaros, Jessica Johnson, Kathryn Adamson, Damion Bailey, Ronan Tegala, Scott Edmonds, Susan Ndagire, Spyridon Gennatas, Alexandros Georgiou, Sharmistha Ghosh, Karapanagiotou Eleni, Debra Josephs, Emma McLean, Hong Hoi Ting, James Spicer, Vicky Goh, Gary Cook
Research output: Contribution to journal › Meeting abstract › peer-review
Fingerprint
Dive into the research topics of 'PD-L1 imaging with [99mTc]NM-01 SPECT/CT predicts early metabolic response to pembrolizumab with or without chemotherapy in advanced non-small cell lung cancer (NSCLC): results from the PECan study.'. Together they form a unique fingerprint.